Clinical Chemistry AACC Online Job Center
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Clinical Chemistry 51: 2226, 2005; 10.1373/clinchem.2005.059626
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit an electronic Letter to
the Editor about this paper
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by van Weemen, B. K.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by van Weemen, B. K.
Related Collections
Right arrow Clinical Immunology
Right arrow Proteomics and Protein Markers
Right arrow Automation and Analytical Techniques
(Clinical Chemistry. 2005;51:2226.)
© 2005 American Association for Clinical Chemistry, Inc.

Perspectives

The Rise of EIA/ELISA

Bauke K. van Weemen

Riethoven, 5561TP 22 The Netherlands

The first 20% of the full text of this article appears below.

Elsewhere in this issue of Clinical Chemistry, Lequin (1) tells the story of how, in the late 1960s, enzyme immunoassay (EIA)/ELISA was conceived and how the technology subsequently found wide application in biomedical analysis. When we started the project at Organon, we certainly did not have the vision that it would lay the foundation for billions of future laboratory analyses. The main reason for starting the project was that Organon’s management liked the success of the immunochemical pregnancy tests that had been introduced some years before (based on inhibition of hemagglutination or latex agglutination), but felt that the cumbersome and time-consuming test procedures formed a threat to continued success. A simple dip-and-read strip giving a color change seemed a more secure basis for future success. Thus, Anton Schuurs’ proposal to explore the potential of enzymes linked to antigens or antibodies for immunochemical reactions with a colorimetric endpoint found approval. Of course, we used the pregnancy hormone human chorionic . . . [Full Text of this Article]






HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2005 by the American Association for Clinical Chemistry.